|
Global Antibody Contract Manufacturing Market (2020 to 2030)
Tuesday, April 7, 2020
DUBLIN, March 30, 2020 The "Antibody Contract Manufacturing Market, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies.
The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:
-- A detailed review of the overall landscape of companies, offering
contract services for the manufacturing of antibodies, along with
information on year of establishment, company size, scale of operation
(preclinical, clinical and commercial), location of headquarters, number
of manufacturing facilities and location of these facilities, type of
antibody manufactured (monoclonal antibodies, bispecific antibodies and
polyclonal antibodies), type of expression systems used (mammalian,
microbial and others), fill / finish operations and affiliations to
regulatory agencies.
-- A competitiveness analysis of key players engaged in this domain,
featuring an assessment based on their supplier strength (related to the
experience of a contract manufacturer), and service strength (which
takes into account the size of service portfolio and scale of
operation).
-- A benchmark analysis, highlighting the key focus areas of small,
mid-sized and large companies, comparing their existing capabilities
within and beyond their respective (geography-based) peer groups.
-- An analysis of the various partnerships pertaining to contract
manufacturing of antibodies, which have been established since 2013,
based on several parameters, such as the year of agreement, type of
partnership, project scale and focus therapeutic area.
-- An analysis of the various expansion initiatives undertaken by service
providers, in order to augment their respective antibody manufacturing
capabilities, over the period 2017-2019 (till October), taking into
consideration parameters, such as year of expansion, type of expansion
(capacity expansion, facility expansion and new facility), type of
antibodies manufactured and location of manufacturing facility.
-- An estimate of the overall, installed capacity for manufacturing
antibodies based on data reported by industry stakeholders in the public
domain; it highlights the distribution of available antibody production
capacity on the basis of company size (small, mid-sized, large and very
large firms), scale of operation (preclinical, clinical and commercial),
and key geographical regions (North America, Europe, Asia).
-- Informed estimates of the annual commercial and clinical demand for
antibodies, based on various relevant parameters, such as target patient
population, dosing frequency and dose strength.
-- Elaborate profiles of the key industry players that offer contract
manufacturing services at all scales of operation and have more than two
manufacturing facilities. Each profile features a brief overview of the
company, information on its service portfolio, details related to its
manufacturing capabilities and facilities, and an informed future
outlook.
-- A case study comparing the key characteristics of large molecule and
small molecule drugs, along with details on the various steps and
challenges involved in their respective manufacturing processes.
-- A discussion on affiliated trends, key drivers and challenges, under a
SWOT framework, which are likely to impact the industry's evolution,
including a Harvey ball analysis, highlighting the relative effect of
each SWOT parameter on the overall pharmaceutical industry.
The report features detailed transcripts of interviews held with the following individuals:
-- Dietmar Katinger, Chief Executive Officer, Polymun Scientific
-- David C Cunningham, Director Corporate Development, Goodwin
Biotechnology
-- Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY COMPETITIVE ANALYSIS
6. COMPANY PROFILES
7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES
8. BENCHMARK ANALYSIS
9. PARTNERSHIPS
10. RECENT EXPANSIONS
11. CAPACITY ANALYSIS
12. DEMAND ANALYSIS
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
14. SWOT ANALYSIS
15. FUTURE OF THE ANTIBODY CMO MARKET
16. INTERVIEW TRANSCRIPTS
17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS
18. APPENDIX 2: TABULATED DATA
19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
-- AbbVie Contract Manufacturing
-- Abcuro
-- Abdi Ibrahim
-- A-Bio Pharma
-- ABL
-- ABL Bio
-- Absolute Antibody
-- Abzena
-- AC Immune
-- Acticor Biotech
-- Actinium Pharmaceuticals
-- Adagene
-- Affinita Biotech
-- Affinity Life Sciences
-- AGC Biologics
-- Ajinomoto Althea
-- Alcami
-- Aldevron
-- Alethia Biotherapeutics
-- Allele Biotechnology & Pharmaceuticals
-- Alligator Bioscience
-- Alvotech
-- Annular Biotech
-- Antibodies Incorporated
-- Antibody Production Services (division of Life Science Group)
-- Arabio
-- Arcus Biosciences
-- argenx
-- ASKA Biotech
-- ASLAN Pharmaceuticals
-- AURA Biotechnologies
-- AutekBio
-- Avid Bioservices
-- Avioq
-- Axcellerate Pharma
-- Batavia Biosciences
-- Baxter BioPharma Solutions
-- Bayer
-- Baylor Scott & White Research Institute
-- BeiGene
-- Bharat Serums and Vaccine
-- BIBITEC
-- BINEX
-- BioInvent International
-- BioLineRx
-- Biomay
-- Biomedical Advanced Research and Development Authority (BARDA)
-- BiosanaPharma
-- Biosynergy EUROPE
-- BioTechnique
-- Biovian
-- BioVolutions
-- BioXcellence (Boehringer Ingelheim)
-- BJ Bioscience
-- Brii Biosciences
-- Bristol-Myers Squibb
-- Bruker
-- Calypso Biotech
-- CANbridge
-- Capralogics
-- Catalent
-- Catalent Biologics
-- Cell Culture Company
-- Cell Essentials
-- Celonic
-- Center of iPS Cell Research and Application, Kyoto University
-- Cerbios-Pharma
-- Changchun High & New Technology Industry
-- ChemPartner
-- Chiome Bioscience
-- CinnaGen
-- Citryll
-- CMAB Biopharma
-- CMC Biologics
-- Cobra Biologics
-- Compugen
-- Cook Pharmica
-- Creative Biolabs
-- CytoDyn
-- Cytovance Biologics
-- DaTaMabs
-- Diatec Monoclonals
-- DM Bio
-- Dyax
-- And Many Many More!
For more information about this report visit https://www.researchandmarkets.com/r/ta244f
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-antibody-contract-manufacturing-market-2020-to-2030-301031600.html
SOURCE Research and Markets
|
|
|
|
The Internet Society Announces New Appointment to the Public Interest Registry Board of Directors | Apr 24, 2024
|
|
Happiest Minds develops GenAI chatbot for Happiest Health | Apr 24, 2024
|
|
TASJEEL.AE UNVEILS INNOVATIVE AI-POWERED DOMAIN SEARCH IN PARTNERSHIP WITH TELECOMMUNICATIONS AND DIGITAL GOVERNMENT REGULATORY AUTHORITY | Apr 24, 2024
|
|
Pedia.com Releases White Paper on Historic Offering, Underscores the Power of Credibility Marketing | Apr 24, 2024
|
|
Arcfield awarded $93M follow-on contract to continue development of cross-domain cyber solutions with U.S. Air Force | Apr 24, 2024
|
|
Alpha Omega announces Rob Brown as Senior Vice President of National Security Solutions | Apr 24, 2024
|
|
CGI's Hotscan360 solution named a market leader for helping enterprises address financial crime compliance | Apr 24, 2024
|
|
Immuta Launches Domains Policy Enforcement Capability to Simplify Enterprise-wide Data Security and Governance | Apr 24, 2024
|
|
DFIN to Announce First-Quarter Results and Host Investor Conference Call on May 1, 2024 | Apr 24, 2024
|
|
LED Billboard Market to Reach $9,795.2 million, Globally, by 2032 at 10.8% CAGR: Allied Market Research | Apr 24, 2024
|
|
|
|